Literature DB >> 3422225

D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro.

A Gruber1, C Peterson, P Reizenstein.   

Abstract

Leukemic cells isolated from peripheral blood from 6 patients with chronic lymphocytic leukemia, immunocytoma and prolymphocytic leukemia were incubated with vincristine (10 nM) with and without racemic verapamil and its L- and D-isomers (6.6 microM). Verapamil increased vincristine accumulation in all cells, the increase varying between 100 and 700%. Racemic verapamil and the L- and D-isomer increased cellular vincristine accumulation to the same extent. The verapamil effect could not be reversed by increasing the calcium concentration in the incubation medium (final concentration 2.5-5.0 mM). The results indicate that the mechanism behind the effect of verapamil on cellular accumulation of vincristine does not depend upon changes in calcium transport.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3422225     DOI: 10.1002/ijc.2910410211

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Randomised trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer: first results.

Authors:  U Gatzemeier; A Schneider; J von Pawel
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Dexverapamil to overcome epirubicin resistance in advanced breast cancer.

Authors:  B Thürlimann; N Kröger; J Greiner; K Mross; J Schüller; E Schernhammer; K Schumacher; G Gastl; J Hartlapp; H Kupper
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects.

Authors:  Li-Mei Zhao; Xiao-Jing He; Feng Qiu; Ya-Xin Sun; Jesse Li-Ling
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

4.  Establishment and characterization of a multidrug-resistant human bladder carcinoma cell line RT112/D21.

Authors:  O Seemann; M Muscheck; M Siegsmund; H Pilch; C T Nebe; J Rassweiler; P Alken
Journal:  Urol Res       Date:  1995

5.  Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.

Authors:  E Roller; B Klumpp; J Krause; M Eichelbaum; K Schumacher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition.

Authors:  P Bhatia; M Kolinski; R Moaddel; K Jozwiak; I W Wainer
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

Review 7.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.

Authors:  J Zacherl; G Hamilton; T Thalhammer; M Riegler; E P Cosentini; A Ellinger; G Bischof; M Schweitzer; B Teleky; T Koperna
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  In vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine.

Authors:  P Deloron; L K Basco; B Dubois; C Gaudin; F Clavier; J Le Bras; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.